These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28817386)

  • 21. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 23. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
    Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
    Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR; Carey DJ; Gogoi R
    BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.
    Huang GS; Lopez-Barcons L; Freeze BS; Smith AB; Goldberg GL; Horwitz SB; McDaid HM
    Clin Cancer Res; 2006 Jan; 12(1):298-304. PubMed ID: 16397055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
    Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
    Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
    Li W; Zhai L; Tang Y; Cai J; Liu M; Zhang J
    Oncol Res; 2012; 20(2-3):49-59. PubMed ID: 23193911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
    Voloshin T; Gingis-Velitski S; Bril R; Benayoun L; Munster M; Milsom C; Man S; Kerbel RS; Shaked Y
    Blood; 2011 Sep; 118(12):3426-35. PubMed ID: 21685373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
    Pusic I; DiPersio JF
    Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
    Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
    Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
    Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA; Ngo H; Martin MC; Wolf JK
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
    Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
    Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
    Zhou KX; Xie LH; Peng X; Guo QM; Wu QY; Wang WH; Zhang GL; Wu JF; Zhang GJ; Du CW
    Cancer Lett; 2018 Apr; 418():196-203. PubMed ID: 29317253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
    Shen Y; Zhang XY; Chen X; Ren ML; Cai YL
    J Cancer Res Ther; 2016; 12(2):657-62. PubMed ID: 27461627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
    Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
    Engle DB; Belisle JA; Gubbels JA; Petrie SE; Hutson PR; Kushner DM; Patankar MS
    Gynecol Oncol; 2009 Mar; 112(3):631-6. PubMed ID: 19263582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.